Author:
Borad Mitesh J.,Soman Arundhati D.,Benjamin Martin,Casa Daniel,Tembe Waibhav D.,Piper Barbara F.,Ramanathan Ramesh,Tibes Raoul,Jameson Gayle,Ansaldo Karen,Von Hoff Daniel D.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference49 articles.
1. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever M (2006) Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12:3997–4003
2. Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362–3371
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (2005) Guidance for Industry: E14 Clinical Evaluation of QT/Qtc Interval Prolongation and Proarrhythmic Potential for Nonarrhythmic Potential for Non-Antiarrhythmic Drugs. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf . Accessed 19 September 2012
4. Committee for Proprietary Medicinal Products (CPMP) (1997) Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf Accessed on 11 September 2012
5. Haddad PM, Anderson IM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:1649–1671
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献